Everolimus for Functional Neuroendocrine Tumours of Gastrointestinal or Lung Origin


( Last Updated : April 6, 2022)
Project Line:
Reference List
Project Sub Line:
Reference List
Project Number:
RA1212-000

Details


Question

  1. What is the clinical effectiveness of everolimus for functional neuroendocrine tumours of lung origin?
  2. What is the clinical effectiveness of everolimus for functional neuroendocrine tumours of gastrointestinal origin?
  3. What is the cost effectiveness of everolimus for functional neuroendocrine tumours of lung origin?
  4. What is the cost effectiveness of everolimus for functional neuroendocrine tumours of gastrointestinal origin?
  5. What are the evidence-based guidelines regarding the use of everolimus for functional neuroendocrine tumours of gastrointestinal or lung origin?

Key Message

No evidence was identified regarding the clinical effectiveness of everolimus for functional neuroendocrine tumours of lung origin.

No evidence was identified regarding the clinical effectiveness of everolimus for functional neuroendocrine tumours of gastrointestinal origin.

No evidence was identified regarding the cost effectiveness of everolimus for functional neuroendocrine tumours of lung origin.

No evidence was identified regarding the cost effectiveness of everolimus for functional neuroendocrine tumours of gastrointestinal origin.

One evidence-based guideline was found regarding the use of everolimus for functional neuroendocrine tumours of gastrointestinal or lung origin.